blok 12 - it 9 - farmakokinetik 2 - stz
DESCRIPTION
niceTRANSCRIPT
![Page 1: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/1.jpg)
Pharmacokinetics
Sutomo TanzilDept.of Pharmacology, Faculty of Medicine, Sriwijaya University
![Page 2: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/2.jpg)
The movement of drug molecules across cellular barriers (1)
To traverse cellular barriers (e.g.GI mucosa, renal tubule, blood-brain barrier, placenta), drugs have to cross lipid membranes.
Drugs cross lipid membranes mainly (a) by passive diffusional transfer and (b) carrier-mediated transfer
The main factor t/ determines the rate of passive diffusional transfer across membranes is a drug’s lipid solubility. Molecular weight is a less important factor.
![Page 3: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/3.jpg)
The movement of drug molecules across cellular barriers (2)
With weak acids or bases only the unionised forms can diffuse across lipid membrane; this gives rise to pH partition.
pH partition means t/ weak acids tend to accumulate in compartments of relatively high pH, whereas weak bases do the reverse.(ion trapping phenomenon)
Carrier-mediated transport is important for some drugs t/ are chemically related to endogenous substances.
![Page 4: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/4.jpg)
![Page 5: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/5.jpg)
Passive diffusional transfer
Lipid solubility pH & ionization Not selective, no energy required,
not saturable, cannot be inhibited pH partition & ion trapping Most drugs across cell membrane
by this transfer.
![Page 6: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/6.jpg)
![Page 7: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/7.jpg)
![Page 8: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/8.jpg)
Carrier-mediated Transport(CMT)
Carrier molecule: a protein which binds molecules or ions, and releases them on the other side of the membrane.
CMT may operate without energy by facilitating the process of transfer in the direction of its electrochemical gradient and the mechanism is called facilitated diffusion. Eg.the transfer of glucose across a muscle cell membrane mediated by GLUT4.
CMT can also occur against an electrochemical gradient and is called active transport. Eg.: sodium pumps, Na-Ca exchange.
CMT shows the characteristic of saturation, and can be inhibited competitively by a second ligand that binds the carrier.
![Page 9: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/9.jpg)
![Page 10: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/10.jpg)
Intravenous administration (i.v)
Absorption circumvented w/ potentially immediate effects. Suitable for large volume & for irritating substances.
Valuable for emergency use Permits titration of dosage Usually required for high-molecular weight protein
and peptide drugs Increased risk of adverse effects The solution must be injected slowly as a rule Not suitable for oily solutions or poorly soluble
substances.
![Page 11: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/11.jpg)
Subcutaneous administration (s.c)
Absorption is prompt, from aqueous solution, slow and sustained from repository preparations.
Suitable for poorly soluble suspensions and for instillation of slow-release implants
Not suitable for large volumes Possible pain or necrosis from
irritating substances.
![Page 12: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/12.jpg)
Intramuscular administration (i.m.)
Absorption is prompt from aqueous solution, slow and sustained from repository preparations.
Suitable for moderate volumes, oily vehicles, and some irritating substances.
Precluded during anticoagulant therapy, and may interfere w/ interpretation of certain diagnostic tests (e.g.creatine kinase)
![Page 13: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/13.jpg)
Oral/Enteral administration
Absorption is variable, depends on many factors
Most common method of drug adminis-tration.It is also the safest,most conve-nient, and most economical. Disadvantages include limitation of absorption of some drugs because of their physical characteristics (eg.water solubility), it also requires patient compliance
Bioavailability is potentially erratic and incomplete.
![Page 14: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/14.jpg)
Drug absorption and bioavailability
Drugs w/ low lipid solubility are poorly absorbed from the gut.
A few drugs (eg.levodopa) are absorbed by CMT. Absorption from the gut depends on: -GI motility, -GI pH,
particle size, -physicochemical interaction with gut contents (eg. Ca and tetracycline antibiotics)
Bioavailability is the fraction of an ingested dose of a drug that gains acces to the systemic circulation. It may be low because absorption is incomplete, or because the drug is metabolised in the gut wall or liver before reaching the systemic circulation.
Bioequivalence implies that if one formulation of a drug is substituted for another no clinical untoward consequences will ensue.
![Page 15: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/15.jpg)
Methods for delaying absorption
Addition of adrenaline (epinephrine) to a local anesthetic
‘slow-release’ form : procaine-penicillin,medroxyprogesterone acetate, testosterone propionat, flufenazine decanoate
Insulin zinc suspensions Subcutaneous implantation of solid
pellets
![Page 16: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/16.jpg)
Drug distribution (Vd)
Vd : the volume of plasma that would contain the total body content of the drug at a concentration equal to that in the plasma.
Lipid insoluble drugs :confined to plasma and the interstitial fluids; most do not enter the brain .
Lipid-soluble drugs reach all compartments, and may accumulate in fat.
For drugs that accumulate outside the plasma compartment (eg. in fat, or being bound to tissues) Vd may exceed total body volume.
![Page 17: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/17.jpg)
![Page 18: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/18.jpg)
![Page 19: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/19.jpg)
![Page 20: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/20.jpg)
Drug metabolism
Phase I reactions:oxidation,reduction & hydrolysis. These usually form more reactive products,sometimes pharmacologically active, toxic or carcinogenic. Phase I oftenly involve cytochrome P450 enzymes.
Phase II reactions : conjugation (eg.glucuronidation) of a reactive group (often inserted during phase I) and form inactive and readily excretable products.
Some conjugated products are excreted via bile, are reactivated in the intestine and then reabsorbed.
Induction of enzymes by other drugs and chemicals can greatly accelerate hepatic drug metabolism.
Some drugs show rapid “first-pass” hepatic metabolism, and thus poor oral bioavailability.
![Page 21: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/21.jpg)
![Page 22: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/22.jpg)
![Page 23: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/23.jpg)
![Page 24: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/24.jpg)
![Page 25: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/25.jpg)
Inhibition of P450
Ketoconazole (an antifungal) which forms a complex with CYP3A4, causes a non-competitive inhibition with a risk of a fatal cardiac arrhythmia if the drug is given concomitantly with terfenadine (an antihistamine).
![Page 26: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/26.jpg)
Induction of P450
Enzyme inducers: ethanol,rifampicin, carbamazepine,increase the activity of microsomal oxidase and conjugating systems when administered repeatedly
![Page 27: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/27.jpg)
![Page 28: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/28.jpg)
Glomerular filtration
Drugs w/ MW <20,000 can cross the glomerular filter, but plasma albumin (MW 68,000) cannot.
If a drugs is highly bound to plasma albumin (eg. Warfarin 98% bound), its concentration in glomerular filtrate is very low (only 2% warfarin).
![Page 29: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/29.jpg)
Tubular secretion
20% of renal plasma flow is filtered through the glomerulus, leaving 80% of the delivered drug to pass on to the peritubular capillaries of the proximal tubule. Here drug molecules are transferred to the tubular lumen by 2 independent carrier systems.One of these transport acidic drugs, while the other handles organic bases.
These active transport can transport drug molecules against an electrochemical gradient and can, therefore , reduce the plasma concentration nearly to zero. Since 80% of the drug delivered to the kidney is presented to the carrier, tubular secretion is potentially the most effective mechanism of renal drug elimination, even when most of the drug is bound to plasma protein (e.g. penicillin)
![Page 30: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/30.jpg)
Diffusion across the renal tubule
As the glomerular filtrate traverses the tubule, water is reabsorbed, so that the volume of urine only about 1% of the filtrate.
High-lipid soluble drugs are excreted slowly,while polar &low lipid soluble drugs remain in the tubule & its concentration in the urine is 100 times >than in plasma.
The ion-trapping effect :a basic drug is more rapidly excreted in an acid urine, because the low pH within the tubule favours ionization and thus inhibits reabsorption.
![Page 31: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/31.jpg)
![Page 32: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/32.jpg)
![Page 33: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/33.jpg)
Biliary excretion and enterohepatic circulation
Liver cells transfer various substances, including drugs, from plasma to bile by means of transport systems similar to those of the renal tubule and which involve P-glycoprotein.
Drug conjugates (particularly glucoronides) are concentrated in the bile and delivered to the intestine where the glucuronide is usually hydrolysed, releasing active drug once more. Free drugs can then be reabsorbed and the cycle repeated (enterohepatic circulation).
Examples :morphine, ethinylestradiol, and rifampicin.
![Page 34: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/34.jpg)
![Page 35: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/35.jpg)
![Page 36: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/36.jpg)
![Page 37: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/37.jpg)
Effect of variation in rate of absorption
Absorption rate constant , kabs , is directly proportional to the amount of drug which is still unabsorbed
Area under the curve (AUC) is directly proportional to the total amount of drug that enters the plasma.
Oral Bioavailability = AUCoral / AUCiv
Intravenous bioavailability = 100%
![Page 38: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/38.jpg)
Saturation kinetics
E.g. Ethanol, phenytoin, salicylate The rate of disappearance of ethanol
from the plasma is constant at about 4 mmol/L per hour irrespective of its plasma concentration.
Also oftenly termed as ‘zero-order kinetics’
The rate of drug metabolism by hepatic enzymes reaches a maximum at low plasma concentration.
![Page 39: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/39.jpg)
![Page 40: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/40.jpg)
![Page 41: BLOK 12 - IT 9 - Farmakokinetik 2 - STZ](https://reader035.vdocuments.us/reader035/viewer/2022062409/55cf949b550346f57ba32918/html5/thumbnails/41.jpg)
References and Further Reading
Brunton,L.L.; et al.(2006). Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th Ed.,McGraw-Hill Medical Publishing Division, USA.
Katzung,B.G.(2007).Basic&Clinical Pharmacology,10th Ed., McGraw-Hill,USA.
Rang & Dale (2003). Pharmacology, 5th Ed.,Churchill Livingstone, London, UK.
Staf Pengajar Dep.Farmakologi FK Unsri (2008). Kumpulan Kuliah Farmakologi, Edisi 2, EGC,Jakarta.